Amazon.com (NASDAQ: AMZN ) has a love for round figures. After stabilizing through the pandemic, Amazon traded between $150 to $200 till 2022, fluctuating between the support and resistance. Through the rate cut pressures of 2022-23, the trading range became $100 to $150. Almost a buy around $100 and exit around $150I am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimizatio ...

Here’s How Sean ‘Diddy’ Combs’ Criminal Conviction Could Help Plaintiffs In His Dozens Of Civil Lawsuits https://t.co/Zfdp2vVs1p https://t.co/Zfdp2vVs1p ...

Core Viewpoint - Air France-KLM is initiating proceedings to acquire a majority stake in SAS, increasing its current stake from 19.9% to 60.5% through the acquisition of shares held by Castlelake and Lind Invest, while the Danish State will retain a 26.4% stake [2][3][10]. Group 1: Acquisition Details - The acquisition will allow Air France-KLM to control SAS, making it a subsidiary and enabling full integration across various business areas, including loyalty programs [5]. - The transaction's value will be determined at closing based on SAS's latest financial performance, including EBITDA and Net Debt [3]. - The ambition is to close the transaction in the second half of 2026, subject to regulatory clearances and satisfaction of all conditions [4][10]. Group 2: Strategic Rationale - Air France-KLM's interest in this acquisition is driven by SAS's significant improvement in financial and operational performance, as well as the success of their current commercial cooperation [6]. - The acquisition reflects the successful turnaround of SAS and aims to unlock synergy potential, confirming Air France-KLM's expansion in the Scandinavian market [10]. Group 3: SAS Overview - As of June 2025, SAS operates 138 aircraft, serves over 130 destinations, and carried more than 25 million passengers in 2024 [11]. - SAS generated revenue of €4.1 billion in the full year 2024 and has over 8 million Eurobonus members [11]. - The current shareholding structure of SAS includes Castlelake (32.0%), Danish State (26.4%), Air France-KLM (19.9%), Lind Invest (8.6%), and others (13.1%) [11].

How This Chicago Private Equity Firm Scored The Biggest Exit Of 2025 https://t.co/q2M1RiA1u1 https://t.co/q2M1RiA1u1 ...

What's going on with gambler @qwatio recently?After being liquidated 10 times, he continued to short $BTC and once again opened a short of 21 $BTC($2.3M) at a low price($109,135).Short the lows. Get liquidated. Repeat.https://t.co/gEEohT6N76 https://t.co/NuwGJ0e9fGLookonchain (@lookonchain):Gambler @qwatio caught in a savage liquidation storm!He was liquidated 8 times in 5 hours, with a total of 1,177 $BTC($128.3M) and 34,466 $ETH($86.82M) liquidated.The loss exceeded $15M in just 10 days!https://t.co/qQ7IO ...

The latest edition of Pointed, Bloomberg’s weekly news quiz, is now live:• Wager your points on categories you *think* you know• Leverage your bets on questions you *know* you know• Don't forget to answer wiselyPlay now and share your results https://t.co/mtvjmSBpIL ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, as well as the CONNECT2 study's suitability for FDA approval [4]. - It is claimed that due to these misrepresentations, PepGen was likely to halt the CONNECT2 study, leading to overstated clinical, regulatory, and commercial prospects for PGN-ED051 [4]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result of the misleading statements [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong reputation in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3].

How This Chicago Private Equity Firm Scored The Biggest Exit Of 2025 https://t.co/vAeMb54Bue https://t.co/vAeMb54Bue ...

Core Insights - Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases and small molecule therapies for other ophthalmic disorders [1][3] - The company granted equity awards to two new non-executive employees as an inducement for employment, consisting of stock options and restricted stock units (RSUs) [1][2] Equity Awards Details - The equity awards include stock options for 240,000 shares and 150,000 RSUs, with the stock options having an exercise price of $0.94, equal to the closing price on the grant date [2] - Stock options vest over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting quarterly thereafter; RSUs vest in four equal installments on each anniversary of the grant date [2] Company Pipeline - Opus Genetics is developing AAV-based gene therapies targeting inherited retinal diseases such as Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa [3] - The lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-related mutations and has shown promising early results [3] - Additional programs include OPGx-BEST1 for BEST1-related retinal degeneration and a Phase 3-ready small molecule therapy for diabetic retinopathy, developed under a Special Protocol Assessment with the FDA [3] - The company is also advancing Phentolamine Ophthalmic Solution 0.75%, which is approved for one indication and is being studied in two Phase 3 programs for presbyopia and dim light vision disturbances [3]

“Individually wrapped Japanese strawberries sell for $19 each.” On “The Intelligence”, @hollieberman explains the fashion for fancy fruit https://t.co/OD2hp6aaPt https://t.co/KPma2Vn97n ...